AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23975860 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus medication education (access to information booklets and eight 30-min face-to-face counselling sessions over 4 weeks)
Number of subjects: 237
Study 23975860 — intervention group
Group type: COMPARATOR
Intervention: No education (control group)
Number of subjects: 237
Study 21964996 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (400/100 mg twice daily)
Number of subjects: 242
Study 21964996 — intervention group
Group type: EXPERIMENTAL
Intervention: atazanavir/ritonavir (300/100 mg once a day)
Number of subjects: 242
Study 21964996 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (600 mg once a day)
Number of subjects: 242
Study 18638591 — intervention group
Group type: EXPERIMENTAL
Intervention: Semicompliant balloon (SC; Maverick(2))
Number of subjects: 301
Study 18638591 — intervention group
Group type: COMPARATOR
Intervention: Noncompliant balloon (NC; Quantum)
Number of subjects: 301
Study 15978714 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil liner bond II (LB) with hybrid resin composite (Clearfil AP-X)
Number of subjects: 72
Study 15978714 — intervention group
Group type: COMPARATOR
Intervention: Single bond (SB) with hybrid resin composite (Clearfil AP-X)
Number of subjects: 72
Study 12888226 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 12888226 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers, beta-blockers, spironolactone
Number of subjects: 0
Study 12888226 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent heart failure guidelines (European Society of Cardiology and American College of Cardiology/American Heart Association)
Number of subjects: 0
Study 11141388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin (LVF), 500 mg v.o. every 24 h
Number of subjects: 84
Study 11141388 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amoxicillin/clavulanate (AMX/CL), 1.02 g i.v. every 8 h
Number of subjects: 84
Study 11141388 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (CTX), 1 g i.v. every 12 h
Number of subjects: 84
Study 9099463 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 99
Study 9099463 — intervention group
Group type: COMPARATOR
Intervention: Triazolam (0.5 mg, twice the recommended dose)
Number of subjects: 99
Study 9099463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 8442983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue application after surgery
Number of subjects: 114
Study 8442983 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 114
Study 3646716 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertion training
Number of subjects: 92
Study 3646716 — intervention group
Group type: EXPERIMENTAL
Intervention: First aid instruction
Number of subjects: 92
Study 3646716 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertion/first aid
Number of subjects: 92
Study 3646716 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 92
Study 30469333 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (n = 19)
Number of subjects: 32
Study 30469333 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n = 13)
Number of subjects: 32
Study 27211862 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic resistance training
Number of subjects: 87
Study 27211862 — intervention group
Group type: COMPARATOR
Intervention: Usual level of physical activity
Number of subjects: 87
Study 24318654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 240
Study 24318654 — intervention group
Group type: COMPARATOR
Intervention: 1-day psychoeducation control group
Number of subjects: 240
Study 22153774 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE‐associated eczema
Number of subjects: 40
Study 22153774 — intervention group
Group type: COMPARATOR
Intervention: Infants without allergic manifestation
Number of subjects: 40
Study 20934833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention pharmacies received weekly updates on EC, fliers with three key messages on EC, and information, education, and communication materials.
Number of subjects: 17
Study 20934833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention pharmacies
Number of subjects: 17
Study 20934833 — intervention group
Group type: COMPARATOR
Intervention: Control pharmacies
Number of subjects: 17
Study 18481319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative inflammatory markers (CRP, IL-6, IGF-1)
Number of subjects: 68
Study 18481319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative IL-6 levels
Number of subjects: 68
Study 18481319 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who did not develop delirium)
Number of subjects: 68
Study 16536247 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotic administration (as morphine equivalents)
Number of subjects: 30
Study 16536247 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial HCAT administration
Number of subjects: 30
Study 16536247 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent HCAT administrations (postoperative days 1-5)
Number of subjects: 30
Study 12935394 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (RLX) 60 mg daily for 12 months
Number of subjects: 204
Study 12935394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 11065084 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction of supplementary fluids for breast fed infants in the first week of life and avoidance of artificial teats and pacifiers
Number of subjects: 602
Study 9315423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking strategies (telephone interviews, calling parents, reviewing charts, sending surveys, offering incentives)
Number of subjects: 16915
Study 9315423 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tobacco and alcohol use
Number of subjects: 16915
Study 9315423 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of procedures used to track participants
Number of subjects: 16915
Study 8253935 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-culture with granulosa cells
Number of subjects: 10
Study 8253935 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 2882772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous celiprolol (8 mg)
Number of subjects: 24
Study 2882772 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal nitroglycerine (10 mg)
Number of subjects: 24
Study 2882772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of celiprolol and nitroglycerine
Number of subjects: 24
Study 2882772 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol during exercise
Number of subjects: 24
Study 2882772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate therapy during exercise
Number of subjects: 24
Study 2882772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy during exercise
Number of subjects: 24
Study 31881928 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-collection intervention (mailed kits for self-collection of samples for HPV testing)
Number of subjects: 510
Study 31881928 — intervention group
Group type: COMPARATOR
Intervention: Control (scheduling assistance alone)
Number of subjects: 510
Study 29889055 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex training (combination of plyometric and weight training)
Number of subjects: 30
Study 29889055 — intervention group
Group type: COMPARATOR
Intervention: Plyometric training
Number of subjects: 30
Study 29889055 — intervention group
Group type: COMPARATOR
Intervention: Weight training
Number of subjects: 30
Study 26810596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT) detected within the first 30 days after randomization
Number of subjects: 2866
Study 26810596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT) detected after 30 days
Number of subjects: 2866
Study 26810596 — intervention group
Group type: EXPERIMENTAL
Intervention: NSVT detected during the convalescent phase (n=428/1991; 21.5%)
Number of subjects: 2866
Study 24446820 — intervention group
Group type: EXPERIMENTAL
Intervention: Arizona Attorney General's Social Networking Safety Promotion and Cyberbullying Prevention presentation
Number of subjects: 425
Study 22796548 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG:HSA
Number of subjects: 18
Study 22796548 — intervention group
Group type: COMPARATOR
Intervention: ICG alone
Number of subjects: 18
Study 20232240 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualized social intervention including instruction and therapeutic activities targeting social skills, face-emotion recognition, interest expansion, and interpretation of non-literal language.
Number of subjects: 0
Study 20232240 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition (control group).
Number of subjects: 0
Study 17492431 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist-control ventilation (ACV)
Number of subjects: 20
Study 17492431 — intervention group
Group type: COMPARATOR
Intervention: Low pressure support ventilation (low PSV)
Number of subjects: 20
Study 15447920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest (SED group)
Number of subjects: 16
Study 15447920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest with supine treadmill exercise (EX group)
Number of subjects: 16
Study 15447920 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamber study (EX group)
Number of subjects: 16
Study 15447920 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamber study (SED group)
Number of subjects: 16
Study 11273843 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) diet
Number of subjects: 35
Study 11273843 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat (HF) diet
Number of subjects: 35
Study 9602984 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 254
Study 9602984 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (500 mg three times daily for 10 days)
Number of subjects: 254
Study 8011967 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone dose of 0.8 mg kg‐1
Number of subjects: 12
Study 8011967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone dose of 0.66 mg kg‐1
Number of subjects: 12
Study 8011967 — intervention group
Group type: EXPERIMENTAL
Intervention: Both prednisone and prednisolone
Number of subjects: 12
Study 2718915 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 0
Study 2718915 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced changes in fat oxidation
Number of subjects: 0
Study 31446625 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CTG
Number of subjects: 17
Study 31446625 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + ECTG
Number of subjects: 17
Study 31446625 — intervention group
Group type: COMPARATOR
Intervention: CAF-alone (adjacent treated sites)
Number of subjects: 17
Study 26704762 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids supplementation
Number of subjects: 120
Study 26704762 — intervention group
Group type: COMPARATOR
Intervention: Control (no omega-3 supplementation)
Number of subjects: 120
Study 25346460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5-0.7 μg/kg/h)
Number of subjects: 57
Study 25346460 — intervention group
Group type: COMPARATOR
Intervention: Propofol (6-8 mg/kg/h)
Number of subjects: 57
Study 25346460 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Dexmedetomidine and Propofol
Number of subjects: 57
Study 23272985 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment strategy (including pharmacological and non-pharmacological therapy)
Number of subjects: 331
Study 23272985 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CAU)
Number of subjects: 331
Study 23272985 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression treatment (received by 168 patients)
Number of subjects: 331
Study 21489819 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation program for 23 ± 5 days
Number of subjects: 60
Study 21489819 — intervention group
Group type: COMPARATOR
Intervention: Medical standard therapy (physiotherapy)
Number of subjects: 60
Study 19649553 — intervention group
Group type: EXPERIMENTAL
Intervention: First-person shooter game (Half Life)
Number of subjects: 30
Study 19649553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive demands video game (Chessmaster)
Number of subjects: 30
Study 19649553 — intervention group
Group type: COMPARATOR
Intervention: No video game training (Control group)
Number of subjects: 30
Study 16420547 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (mostly semisynthetic penicillin)
Number of subjects: 381
Study 16420547 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin combined with standard treatment
Number of subjects: 381
Study 16420547 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (when deep infection suspected)
Number of subjects: 381
Study 15572743 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational workshops (cognitive-behavioural approach)
Number of subjects: 120
Study 15572743 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 120
Study 11282762 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% O(2) during exercise
Number of subjects: 11
Study 11282762 — intervention group
Group type: COMPARATOR
Intervention: Room air (RA) during exercise
Number of subjects: 11
Study 9227199 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen + 0% nitrogen
Number of subjects: 16
Study 9227199 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% oxygen + 90% nitrogen
Number of subjects: 16
Study 8214916 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride inhalation therapy (5 x 10(‐3) M amiloride in one‐third normal saline four times a day)
Number of subjects: 6
Study 8214916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one‐third normal saline)
Number of subjects: 6
Study 3609190 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher nicotine cigarette (1.4 mg nicotine, 10 mg tar)
Number of subjects: 10
Study 3609190 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower tar cigarette (10 mg tar, 1.4 mg nicotine)
Number of subjects: 10
Study 3609190 — intervention group
Group type: COMPARATOR
Intervention: Cigarettes with the same tar level
Number of subjects: 10
Study 3609190 — intervention group
Group type: COMPARATOR
Intervention: Cigarettes with the same nicotine level
Number of subjects: 10
Study 31811577 — intervention group
Group type: EXPERIMENTAL
Intervention: Conduct disorder
Number of subjects: 30532
Study 30772671 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) for 6 months
Number of subjects: 116
Study 30772671 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy plus external beam radiation
Number of subjects: 116
Study 30772671 — intervention group
Group type: COMPARATOR
Intervention: External beam radiation alone
Number of subjects: 116
Study 30772671 — intervention group
Group type: COMPARATOR
Intervention: No ADT
Number of subjects: 116
Study 28650326 — intervention group
Group type: EXPERIMENTAL
Intervention: CofNovex plus (EMA) syrup
Number of subjects: 220
Study 28650326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 26330422 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W), increased to 150 mg Q2W at Week 12 if LDL-C ≥1.8 mmol/L
Number of subjects: 735
Study 26330422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 735
Study 23793983 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced amenorrhea (CIA) group
Number of subjects: 30
Study 23793983 — intervention group
Group type: COMPARATOR
Intervention: Post-menopausal BC patients undergoing chemotherapy
Number of subjects: 30
Study 23793983 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (pre- and post-menopausal)
Number of subjects: 30
Study 23793983 — intervention group
Group type: EXPERIMENTAL
Intervention: CIA group
Number of subjects: 30
Study 21666789 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplementation
Number of subjects: 612
Study 21666789 — intervention group
Group type: COMPARATOR
Intervention: No multi-nutrient supplementation
Number of subjects: 612
Study 18977585 — intervention group
Group type: EXPERIMENTAL
Intervention: 100U Botulinum toxin (Dysport)
Number of subjects: 24
Study 18977585 — intervention group
Group type: EXPERIMENTAL
Intervention: 140U Botulinum toxin (Dysport)
Number of subjects: 24
Study 18977585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16505650 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day, group A)
Number of subjects: 40
Study 16505650 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 40
Study 12926583 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arm (T)
Number of subjects: 0
Study 12926583 — intervention group
Group type: COMPARATOR
Intervention: Comparator arm (C)
Number of subjects: 0
Study 10856536 — intervention group
Group type: COMPARATOR
Intervention: 40 mg fluvastatin alone
Number of subjects: 333
Study 10856536 — intervention group
Group type: COMPARATOR
Intervention: 400 mg bezafibrate alone
Number of subjects: 333
Study 10856536 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fluvastatin + 400 mg bezafibrate
Number of subjects: 333
Study 10856536 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg fluvastatin + 400 mg bezafibrate
Number of subjects: 333
Study 9200048 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude cervical manipulation twice a week for 3 weeks
Number of subjects: 53
Study 9200048 — intervention group
Group type: COMPARATOR
Intervention: Low-level laser and deep friction massage twice a week for 3 weeks
Number of subjects: 53
Study 7693533 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-protected porcine pancreatic extracts
Number of subjects: 43
Study 7693533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3544353 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymomodulin
Number of subjects: 0
Study 3544353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31987653 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 116
Study 31987653 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 116
Study 31987653 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive phenobarbital
Number of subjects: 116
Study 31987653 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal psychological distress
Number of subjects: 116
Study 31987653 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant medical problems
Number of subjects: 116
Study 31987653 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued maternal substance use
Number of subjects: 116
Study 30445988 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet + beta-cryptoxanthin (HPD+beta-CX)
Number of subjects: 92
Study 30445988 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein diet + beta-cryptoxanthin (NPD+beta-CX)
Number of subjects: 92
Study 30445988 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet + placebo (HPD+placebo)
Number of subjects: 92
Study 30445988 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet + placebo (NPD+placebo)
Number of subjects: 92
Study 26456063 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up and Go Test (TUGT)
Number of subjects: 278
Study 24783914 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1 course consisting of 2 infusions of 1,000 mg each) with background Methotrexate
Number of subjects: 33
Study 24783914 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly) with background Methotrexate
Number of subjects: 33
Study 21083736 — intervention group
Group type: EXPERIMENTAL
Intervention: Fittydent(®)
Number of subjects: 30
Study 21083736 — intervention group
Group type: EXPERIMENTAL
Intervention: Protefix(®)
Number of subjects: 30
Study 21083736 — intervention group
Group type: EXPERIMENTAL
Intervention: Seabond(®)
Number of subjects: 30
Study 21083736 — intervention group
Group type: COMPARATOR
Intervention: Control (no adhesive)
Number of subjects: 30
Study 20367669 — intervention group
Group type: EXPERIMENTAL
Intervention: APS 5% lotion
Number of subjects: 50
Study 20367669 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 50
Study 18588701 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisational music therapy (biweekly sessions for 3 months)
Number of subjects: 85
Study 18588701 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 85
Study 15818486 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative treatment (directly from step I to step III of the WHO analgesic ladder)
Number of subjects: 54
Study 15818486 — intervention group
Group type: COMPARATOR
Intervention: Traditional three-step strategy
Number of subjects: 54
Study 15818486 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative treatment
Number of subjects: 54
Study 12625130 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated mosquito nets (ITNs)
Number of subjects: 0
Study 12625130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ITNs)
Number of subjects: 0
Study 12014724 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/day tegaserod
Number of subjects: 86
Study 12014724 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/day tegaserod
Number of subjects: 86
Study 12014724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 12014724 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod pooled data
Number of subjects: 86
Study 12014724 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod (4 mg/day and 12 mg/day)
Number of subjects: 86
Study 9599499 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for six weeks
Number of subjects: 45